Equities Analysts Offer Predictions for CARM FY2024 Earnings

Carisma Therapeutics, Inc. (NASDAQ:CARM) – Equities researchers at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Carisma Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($1.32) for the year, up from their prior forecast of ($1.33). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Carisma Therapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Carisma Therapeutics’ Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%.

Separately, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Trading Down 1.1 %

Carisma Therapeutics stock opened at $0.84 on Wednesday. The stock has a market cap of $35.11 million, a PE ratio of -0.54 and a beta of 1.49. The stock has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.09. Carisma Therapeutics has a 52 week low of $0.80 and a 52 week high of $3.16. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39.

Institutional Trading of Carisma Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP grew its holdings in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Carisma Therapeutics in the 2nd quarter valued at about $40,000. Barclays PLC grew its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Carisma Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after buying an additional 11,200 shares during the period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.